Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.
Our founder and CSO, Prof. Joen Luirink is a world-leading expert on bacterial protein trafficking and membrane transport systems and his vast knowledge in the area provided the basis for Abera’s innovative vaccine delivery platform.
Abera’s novel vaccine delivery platform was first developed to express complex proteins. But when we developed the possibility to attach proteins on the outside of the membrane, the idea of displaying antigens as a vaccine delivery platform was
Since the start we have collaborated with academia and the biotech industry to develop and refine the platform and designed a number of experimental vaccines against e.g. pneumococcal disease, chlamydia, ETEC and tuberculosis. Many collaborations have received significant financial support from EU (Horizon 2020, Eurostars and Eureka), governments and non-profit health organizations. This has enabled us to advance the technology and build our solid foundation of today.
We strongly believe that vaccines are one of the most powerful tools to save lives and increase health globally. Abera is dedicated to the development of novel vaccines and vaccine strategies to meet these ambitions.
Our mission is to develop vaccine candidates based on our novel vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines.